Table 2.
Summary of adverse events in the Blood First Assay ScreeningTrial Cohort B patients
| Patients who experienced any of the following | Alectinib 900 mg BID (N = 8) | |
|---|---|---|
| AE, all-cause | 8 (100.0) | |
| Grade 3–5 | 7 (87.5) | |
| Grade 5 | 2 (25.0) | |
| Leading to withdrawal from treatment | 3 (37.5) | |
| Leading to dose modification/interruption | 4 (50.0) | |
| Treatment-related AE | 6 (75.0) | |
| Leading to withdrawal from treatment | 1 (12.5) | |
| Leading to dose modification/interruption | 3 (37.5) | |
| SAE | 5 (62.5) | |
| Leading to withdrawal from treatment | 3 (37.5) | |
| Leading to dose modification/interruption | 2 (25.0) | |
| Related to treatment | 2 (25.0) | |
AE – adverse event, BFAST – Blood First Assay Screening Trial, BID – twice daily, SAE – serious adverse events
Data are presented as n (%).